title: Prevention of cytomegalovirus reactivaction after allogenic hematopoietic stem cell transplantation with valganciclovir: single center experience.
authors.affiliation: BMT Unit, Department of Oncology, Military Institute of Health Services, Warsaw, Poland. piotr_rzepecki@poczta@poczta.onet.pl
authors.forename: P
authors.initials: P
authors.lastname: Rzepecki
authors.forename: J
authors.initials: J
authors.lastname: Barzal
authors.forename: T
authors.initials: T
authors.lastname: Sarosiek
authors.forename: S
authors.initials: S
authors.lastname: Oborska
authors.forename: C
authors.initials: C
authors.lastname: Szczylik
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control* / Q000821:virology; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D014184:Transplantation, Homologous; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir